Side effect of metformin trial#

There was a 1% reduction in HbA1c in group 1, 0.7% reduction in group 2 and only 0.4% reduction in group 3. The mean age of patients was 46в™ years, with 54% being males and 46% being females. HbA1c was done at baseline and after three months of therapy along with fasting blood sugars and random blood sugars weekly. Group 1 received Metformin IR 1000 mg twice daily group 2 received metformin XR 1000 mg twice daily and group 3 received metformin XR 500 mg twice daily, for a period of three months. Patients were randomized into 3 groups 30 in each group. A total of 90 type 2 diabetics of both genders were recruited using nonprobability purposive sampling.

Side effect of metformin trial#

This randomized control trial was conducted at Medical and Endocrinology OPD of Jinnah Hospital Lahore.

The objective of this study was to determine whether metformin XR is as effective as Metformin IR in maintaining glycaemic control at equivalent doses or even at reduced doses and to compare the side effect profile of the two preparations.

Metformin XR has better gastrointestinal tolerability and fewer side effects as compared to Metformin IR, with similar efficacy regarding anti-hyperglycaemic effects. Metformin is available as conventional Metformin Immediate Release (MIR) and Metformin Extended Release (MXR). Metformin is the first line therapy, along with lifestyle modification for all type 2 diabetics as recommended by ADA. Diabetes Mellitus type 2 is very common worldwide, with majority of cases in Asia Pacific region.